Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data In Patients With Recurrent Glioblastoma At 2024 American Society Of Clinical Onc...

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging ant

Related Keywords

United States ,Arizona ,Cambridge ,Cambridgeshire ,United Kingdom ,Black Diamond ,American ,Patrick Wen ,Nader Sanai ,Mario Corso ,American Society Of Clinical Oncology ,Oncology At Dana Farber Cancer Institute ,Ivy Brain Tumor Center Clinical ,Nasdaq ,Ivy Brain Tumor Center ,Company Masterkey ,International Conference On Molecular ,Diamond Therapeutics Inc ,Exchange Commission ,Diamond Therapeutics ,American Society ,Clinical Oncology ,Dana Farber Cancer Institute ,Generation Covalent ,Recurrent Glioblastoma ,Dose Escalation Results ,Molecular Targets ,Trigger Trial ,Recurrent High Grade Glioma ,Private Securities Litigation Reform Act ,Annual Report ,United States Securities ,Investor Relations ,